The US Food and Drug Administration (FDA) says safeguards for avoiding unnecessary exposure to medical radiation should be tightened and announced a new three-pronged initiative on Tuesday to increase oversight of the biggest contributors: computed tomography (CT), nuclear medicine studies, and fluoroscopy. The agency announced that the three-pronged initiative "will promote the safe use of medical imaging devices, support informed clinical decision-making, and increase patient awareness of their own exposure". The FDA said CT, nuclear medicine, and fluoroscopic imaging were the greatest contributors to radiation exposure in Americans and use much higher radiation doses than other radiographic methods like standard medical X-rays, dental X-rays and mammography.
Molecular diagnostics company Biocartis and Royal Philips Electronics (NYSE: PHG, AEX: PHI) today announced the signing of an agreement that will result in Biocartis acquiring Philips' technology platform for rapid fully-automated DNA/RNA molecular diagnostic testing. The platform has been designed for applications in a wide range of patient sample testing, including oncology and infectious diseases. Financial details of this agreement were not disclosed. Biocartis will develop and commercialize the platform, together with a menu of tests, through strategic partnerships and will finalize validation of the platform at its newly-established and wholly-owned Dutch subsidiary Biocartis BV.
BD Launches New Device Designed To Improve Safety, Accuracy And Turnaround Time Of Blood Collection In Patients With Fragile Veins
BD Diagnostics, a segment of BD (Becton, Dickinson and Company), announced the launch of BD Microtainer® MAP Microtube for Automated Process for hematology testing. This new product is designed to improve the safety, accuracy and turnaround time of capillary blood collection and testing in patients with veins that can be difficult to access, such as infants, children, oncology patients and the elderly. The new BD Microtainer MAP product is also the first microtube to be fully compatible with most automated hematology instruments, reducing turnaround time and costs associated with sample transfer and relabeling. "Clinical laboratories are focused on preventing specimen identification errors that can lead to misdiagnosis of patients.
RTI Biologics Inc. (RTI) (Nasdaq: RTIX), the Florida-based processor of orthopedic, dental, hernia and other biologic implants, has donated Matrix HD™ sterilized dermis allografts to use in limb salvage procedures for victims of the recent natural disasters in Haiti. A group of surgeons from Barry University and Mercy Hospital in Miami, Fla., will leave this week to treat patients in Haiti, many of whom will need the Matrix HD™ allografts to save their arms or legs from amputation. "These grafts from RTI are very important because we do not have the surgical equipment or facilities available to harvest autografts from the patients, and we can apply these allografts without general anesthesia, " said Dr.
Toshiba Service Earns The Most Top Rankings In IMV ServiceTrak Imaging Cardiovascular X-ray User Survey
As health care facilities today seek the best value in imaging and customer service, Toshiba America Medical Systems, Inc.'s Service organization strives to deliver top-tier service and customer satisfaction. The result of this dedication was once again confirmed by IMV, Ltd., which provides independent analysis of service trends in the imaging industry. In IMV's 2009 ServiceTrak™ Imaging report on cardiovascular X-ray system service, Toshiba received more top rankings than any other imaging vendor. Toshiba's cardiovascular X-ray service received the top ranking in 18 out of 36 attributes, including overall service performance, overall satisfaction with a manufacturer, reliability of hardware and reliability of software.
Excelsior Medical Corporation, one of the leading manufacturers of pre-filled catheter flush syringes, today announced that it has received a Medical Device License from Health Canada for its new, pre-filled catheter lock syringe to be sold in the Canadian marketplace. The syringe contains the first commercially available heparin replacement solution - a combination of 4% Sodium Citrate and 30% Ethanol in water for injection. The solution has similar anticoagulant properties to heparin so it helps maintain catheter patency without the possible negative side affects. The new Excelsior Medical solution has a major advantage over heparin, because it eliminates many of the potentially dangerous complications associated with heparin.